You just read:

Cellenkos, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Treatment-Resistant Guillain-Barré Syndrome

News provided by

Cellenkos, Inc.

Oct 16, 2018, 06:17 ET